Estrogen Receptor Determination Predicts Response to Tamoxifen Therapy

  • J. C. Allegra
  • M. E. Lippman
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 71)

Abstract

Tamoxifen (TAM, ICI 46,474) is a nonsteroidal antiestrogen of the triphenylethylene family. The clinical use of TAM was first reported in 1971 (Cole et al., 1971), and early clinical trials suggested that TAM was useful in the treatment of metastatic breast cancer (Cole et al., 1971; Ward, 1973; Cole et al., 1972). These studies yielded response rates ranging between 15% and 60% with minimal toxicity.

Keywords

Toxicity Estrogen Shrinkage Oncol Tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aitken, S., Lippman, M. E.: A simple computer program for quantification and Scatchard analysis of steroid receptor proteins. J. Steroid Biochem. 8, 77–94 (1977)PubMedCrossRefGoogle Scholar
  2. Breast Cancer Task Force Treatment Committee, National Cancer Institute: Breast cancer: Suggested protocol guidelines for combination chemotherapy trials and for combined modality trials. U.S. Department of Health, Education and Welfare Publication No. (NIH) 77–1192 (1977)Google Scholar
  3. Cole, M. P., Jones, C. T. A., Todd, I. D. H.: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br. J. Cancer 25, 270–275 (1971)PubMedCrossRefGoogle Scholar
  4. Cole, M. P., Jones, C. T. A., Todd, I. D. H.: The treatment of advanced carcinoma of the breast with the anti-oestrogenic agent tamoxifen (ICI 46,474) — a series of 96 patients. Adv. Antimicrob. Antineoplas. Chemother. 2, 529–531 (1972)Google Scholar
  5. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., De Sombre, E. R.: Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monogr. 34, 55 (1971)PubMedGoogle Scholar
  6. Kiang, D. T., Kennedy, B. J.: Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann. Intern. Med. 87, 687–690 (1977)PubMedGoogle Scholar
  7. Lehmann, E. H.: Non-parametries: Statistical methods based on ranks, p. 208. San Francisco: Holden-Day Inc. 1975Google Scholar
  8. Lippman, M. E., Huff, K. K.: A demonstration of androgen and estrogen receptors in human breast cancer using a new protamine sulfate assay. Cancer 38, 868–874 (1976)PubMedCrossRefGoogle Scholar
  9. McGuire, W. L., Carbone, P. P., Sears, M. E., Escher, G. C.: Estrogen receptors in human breast cancer: An overview. In: Estrogen receptors in human breast cancer. McGuire, W. L., Carbone, P. P., Volmer, E. P. (eds.), pp. 1–7. New York: Raven Press 1975Google Scholar
  10. McGuire, W. L., Horwitz, K. B., Pearson, O. H., Segaloff, A.: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39, 2934–2947 (1977)PubMedCrossRefGoogle Scholar
  11. Morgan, L. R., Schein, P. S., Woolley, P. V., Hoth, D., Macdonald, J., Lippman, M., Posey, L. E., Beazley, R. W.: Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat. Rep. 60, 1437–1443 (1976)PubMedGoogle Scholar
  12. O’Connor, T., Rosenbaum, C., Cardellicchio, D., Cohen, J. L., Stolbach, L.: Estrogen receptor (ER) predicts tamoxifen (Tarn) response in advanced breast cancer (Br). Proc. Ann. Meet. Am. Soc. Clin. Oncol. 19, 374 (1978)Google Scholar
  13. Ward, H. W. C.: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J. 1973 I, 13–14CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • J. C. Allegra
    • 1
  • M. E. Lippman
    • 1
  1. 1.Medicine Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations